Navigation Links
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,,Its New Long Acting Drug For Erectile Dysfunction

All Endpoints Met - Up to 88% Efficacy

SEOUL, Korea, March 28, 2007 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. announced today that it has completed a 340 patient phase 2b "at-home" clinical study for udenafil, its new long acting (12 hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in the U.S. was a randomized, double-blind, placebo controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug baseline period, 340 men with ED of broad etiology and severity were randomized to one of four treatment groups: Placebo, udenafil 50mg, udenafil 100mg or udenafil 150mg. The drug treatment period was 12 weeks with evaluations every 4 weeks. The primary efficacy endpoints were the change in the International Index of Erectile Function (IIEF) Erectile Function Domain (EF) score from baseline to final visit; mean vaginal penetration success rates and mean intercourse completion rates calculated from the Sexual Encounter Profile (SEP) questions 2 and 3, respectively. The study had several secondary efficacy measurements including changes in scores from the other IIEF domains, scores from the remaining SEP questions, changes from baseline in the Patient Self-Assessment Questionnaire (PSAE) and the mean Global Assessment Score (GAQ).

All primary efficacy endpoints were statistically significant compared to placebo. The mean vaginal penetration success rates were 72% (50mg), 88% (100mg) and 82% (150mg) and significantly (p<0.001) higher compared to the 60% observed in the placebo group. The mean intercourse completion rates were 53% (50mg), 66% (100mg) and 69% (150mg) and significantly (p<0.001) higher compared to the 38% observed in the placebo group. Patients reporting improved erections after the 12-week course of therapy were 58% (50mg), 80% (100mg) and 73% (150mg) and signif
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... July 10, 2014 Decision Resources Group finds ... the U.S. Food and Drug Administration,s (FDA) approval of ... Velphoro, which was approved by the FDA in November ... disease (CKD) patients on dialysis. Other key ... (US) Q2 2014 : ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Inc., announced today that it acquired all U.S. rights ... Denavir® owned by Novartis.  Denavir (1% penciclovir cream) is ... for the treatment of recurrent herpes labialis (cold sores) ... older.  The topical antiviral cream market in the U.S. ...
... 1 A web-based tool that extracts information from the ... and manage their entire panel of patients. Those are the ... to examine the effectiveness of a panel management tool in ... study, published today in The American Journal of Managed ...
Cached Medicine Technology:New American Therapeutics Acquires Antiviral Drug Denavir® 2Innovative Web-based Tool Helps Doctors Improve Care 2Innovative Web-based Tool Helps Doctors Improve Care 3Innovative Web-based Tool Helps Doctors Improve Care 4Innovative Web-based Tool Helps Doctors Improve Care 5
(Date:7/13/2014)... The North American water storage systems market is estimated to ... 2018, at a CAGR of 21.0%, from 2013 to 2018. ... pace in North America. The U.S. is experiencing high growth ... storage and collection, and the increased spending on modernization and ... healthy rate in Canada, and is rising at a rapid ...
(Date:7/13/2014)... According to a new market research ... Component (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), ... - Forecast and Analysis to 2014-2020", published by ... Market is expected to reach $61.70 Billion by ... 2014 to 2020. , Browse 71 market data ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace wedding ... the company has announced its new selection of elegant ... these outfits are available at discounted prices (from 25 ... is now offering similar discounts for many other wonderful ... other designs for sale, including flower girl dresses, wedding ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... (NYSE: SGP ) will not present ... Miami, on Tuesday, March 10, as previously planned. ... employee communications related to the merger agreement with ... be able to attend the conference.Schering-Plough is an ...
... Catholic Priest Co-Founded Father Martin,s Ashley Treatment Center in ... Joseph C. Martin, S.S., noted authority and lecturer on ... center in Havre de Grace, MD, died today at ... 84.Best known for his lectures on alcoholism as a ...
... 9 NJHA Corporate Services has partnered with ... offer training and consulting services to its member ... The deal comes on the heels of The ... directs healthcare facilities to establish a plan to ...
... The Providence Service Corporation (Nasdaq: ... financial results for its fourth quarter and year ended December ... opens.Providence will hold a conference call at 11:00 a.m. EDT ... same day, Monday, March 16, 2009, to discuss its financial ...
... 9 The BlueCross BlueShield of South Carolina Foundation ... Nurse-Family Partnership program in Horry County to support first ... will begin at noon, March 13, in Ballroom C ... Street, Myrtle Beach, S.C.The BlueCross Foundation is proud to ...
... Most carriers view the procedure as best security against the ... -- Women who know they carry a gene that puts ... for preventive mastectomy, a new study concludes. , Several type ... have a mutated BRCA1 or BRCA2 gene, which is known ...
Cached Medicine News:Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 2Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 3Health News:The Rev. Joseph C. Martin, Leading Authority on Alcoholism and Addiction Treatment, Dies at 84 4Health News:NJHA, McNamara and Associates Inc. Team Up to Provide Strategies for Controlling Workplace Violence 2Health News:Providence Service Corporation to Report Fourth Quarter and Year End 2008 Results on Monday, March 16th Before the Market Opens 2Health News:Providence Service Corporation to Report Fourth Quarter and Year End 2008 Results on Monday, March 16th Before the Market Opens 3Health News:S.C. BlueCross Foundation to Grant More Than $1.3 Million to Support First Time Mothers in Horry County 2Health News:Women With Breast Cancer Gene Favor Preventive Mastectomy 2
... switch control, solid cast aluminum frame, ... folding armrests, multi-position full range articulating ... handle, ergonomically contoured cushions with anti-viral ... of upholstery colors. Optional features: foot ...
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... HPX Streak Retinoscope comes ... and provides 40% more ... scopes and maintains a ... greatly enhances illumination and ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
Medicine Products: